Idec Pharmaceuticals Corporation

Biogen Idec, Inc.

Mitsubishi Tanabe Pharma Corporation

Other

Idec Pharmaceutical Corporation

Mitsubishi Tanabe Pharma Corporat

Roland A Newman

Nabil Hanna

Mitchell E Reff

Darrell R Anderson

William H Rastetter

Peter Brams

Amelia Nancy Black

Cheryl Janne Heard

Edward E Walsh

Soulaima Salim Chamat

Ronald W Raab

Li-Zhen Pan

Eduardo Agustin Padlan

John E Leonard

Marco Gymnopoulos

Anjuli Timmer

Julia Coronella

Ryo Fujita

Dragan Grabulovski

Richard Woods

Isabella Attinger-Toller

Steve Granger

Robyn Richardson

Michela Silacci

Wenjuan Zha

Vincent Blot

Eduardo A Padian

Michael Lyman

Presented herein are novel monoclonal cMET binding agents that are conjugated to pyrrolobenzodiazepine toxins, composition thereof and uses thereof for the treatment of cancer.

Drug conjugates of cMET monoclonal binding agents, and uses thereof

Presented herein, in certain embodiments, are compositions comprising monoclonal binding agents that specifically bind to the extracellular domain of cMET and uses thereof.

CMET monoclonal binding agents, drug conjugates thereof and uses thereof

Presented herein, in certain embodiments, are compositions comprising binding agents that specifically bind to syndecan-1 and uses thereof.

Syndecan-1 (CD138) binding agents and uses thereof

Provided is a bi-specific fusion polypeptide comprising a fynomer sequence that binds to interleukin-17a (IL-17a) and is conjugated to an antibody or subsequence thereof that binds to interleukin-6 receptor (IL-6R). The fusion polypeptide can bind to both IL-17a and IL-6R thereby suppresses, reduces, decreases, inhibits or blocks both IL-17a and IL-6R activities.

Antibody-fynomer conjugates

Disclosed herein are methods of depleting peripheral blood B cells in a human host comprising administering to the host an immunologically active anti-CD20 antibody in an amount effective to deplete peripheral blood B cells in the host.

Expression and use of anti-CD20 Antibodies

Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).

Recombinant anti-CD4 antibodies for human therapy

Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders.

Anti-CD20 antibodies

Disclosed are immunologically active antibodies directed against the CD20 antigen, as well as host cells comprising nucleic acid sequences encoding the light chains and heavy chains of immunologically active antibodies wherein the cell is capable of expressing and secreting an immunologically active chimeric anti-CD20 antibody and methods of using such host cells to make purified antibodies. The antibodies are useful for treating and diagnosing B cell disorders.

Expression and use of anti-CD20 antibodies

The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases; and an immunosuppressant during transplantation of heterologous cells, tissues or organs, cell therapy, and gene therapy.

Treating autoimmune diseases with humanized anti-CD40L antibody

The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases.

Treating allergic diseases with humanized anti-CD40L antibody

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.

Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma

Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies

Methods of treating autoimmune diseases with gp39-specific antibodies

Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma

Growing community of inventors

San Diego, CA, United States of America

Roland A Newman